To print: Select File and then Print from your browser's menu

Title: Selecting The Dose Of Single Radioiodine Therapy For Goitre

URL: http://link.springer-ny.com/link/service/journals/00259/contents/01/00722/

Eur J Nucl Med 2002;29: 480-485. "Dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of 99mTc-pertechnetate thyroid uptake"
04/18/2002 07:56:00 AM
By Mark Greener

The single radioiodine regimen for elderly patients with enlarged thyroid glands and autonomous masses can be based on technetium-99m pertechnetate thyroid uptake under thyrotropin suppression (TcTU[_s). Researchers from University Hospital Bonn, and other centres in Germany and Switzerland, aimed to optimise treatment of diffuse and nodular toxic goitre using single doses of radioiodine based on TcTU_s. This acts as a surrogate for non-suppressible iodine turnover and the functional autonomous mass. The study enrolled 438 patients, average age 70 years, with a mean thyroid volume of 54 ml. Of these, 261 experienced at least one episode of overt hyperthyroidism. The tissue absorbed doses from single radioiodine therapy ranged from 150 Gy for TcTU_s of between 1.5 and 2.49 percent to 300 Gy for a TcTU_s of at least 4.5 percent. Thyroid volume declined by a mean 37 percent a year after treatment. At this time, 96 percent of patients showed normalised TcTU_s and 92 percent showed normal thyrotropin levels. Only 0.9 percent of patients developed hypothyroidism. Five patients showed recurrent hyperthyroidism. The authors recommend selecting the dose of single radioiodine therapy based on TcTU_s for elderly patients with enlarged thyroid glands and autonomous masses, and who are likely to develop iodine-induced hyperthyroidism.

http://link.springer-ny.com/link/service/journals/00259/contents/01/00722/

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.